読み込み中
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
前日終値
$12.75
+$1.74 · +15.80%
日中の時刻はETです。市場データは遅延する場合があります。
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
日中レンジ
現在 $12.75
52週レンジ
現在 $12.75
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
82
大幅な割安
センチメント
56
まちまち
リスク
64
高リスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
日中レンジ
現在 $12.75
52週レンジ
現在 $12.75
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 11.23億 USD | 6.82億 USD | 5.56億 USD | 15.99億 USD | 1.98億 USD |
| 売上原価 | 7114万 USD | 2.03億 USD | 3.44億 USD | 9.03億 USD | — |
| 粗利益 | 10.52億 USD | 4.79億 USD | 2.13億 USD | 6.96億 USD | 1.98億 USD |
| 研究開発 | 3.37億 USD | 3.91億 USD | 7.38億 USD | 12.35億 USD | 25.35億 USD |
| 販売・一般管理 | 1.5億 USD | 3.37億 USD | 4.69億 USD | 4.89億 USD | 2.98億 USD |
| 営業費用 | 4.89億 USD | 7.28億 USD | 7.79億 USD | 13.41億 USD | 18.84億 USD |
| 支払利息 | 2254.7万 USD | 2007.5万 USD | 1441.6万 USD | 1988万 USD | 2112.7万 USD |
| 減価償却費と償却費 | 2761.3万 USD | 4849.6万 USD | 4122.5万 USD | 2905.4万 USD | 1266.1万 USD |
| 営業利益 | 5.63億 USD | −2.49億 USD | −5.67億 USD | −6.45億 USD | −16.87億 USD |
| 純利益 | 4.4億 USD | −1.87億 USD | −5.45億 USD | −6.58億 USD | −17.44億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$18.00
上昇余地（41.18%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年5月10日 | 1:20 | — | — |
発効済み 2019年5月10日
1:20
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI5137.12万0.52%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI4869.75万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM4446.37万0.06%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3544.64万0.02%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2029.8万0.04%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1792.76万0.02%954億 USD0.05%$235+0.80%
Invesco Biotechnology & Genome ETFPBE1581.25万3.75%4.22億 USD0.59%$97.065+2.98%
iShares Biotechnology ETFIBB1337.32万0.13%108.2億 USD0.44%$206.49+3.00%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco Biotechnology & Genome ETFPBEiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
